Android app Apple app link

Chengdu Origen and Vanotech dose first subject in gene therapy trial for wet AMD

By Yahoo! Finance   |   1 month ago
Chengdu Origen and Vanotech dose first subject in gene therapy trial for wet AMD

Chengdu Origen Biotechnology and Vanotech have begun dosing subjects in the Phase I trial VAN-2401, evaluating KH658 gene therapy for wet AMD. The trial aims to assess safety, tolerability, and efficacy through suprachoroidal space administration.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.